Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech

Dr.  Helén Tuvesson takes up the post  as Chief Scientific Officer within Active
Biotech   from   April  1, 2011. Helén  Tuvesson  will  be  reporting  to  Tomas
Leanderson, President & CEO.

Dr.  Tuvesson has worked  in the pharmaceutical  industry for more than 20 years
and  has extensive  experience in  drug development,  from the early preclinical
stage  up to  late clinical  development. Helén  has been on different positions
within  Active Biotech  since 1998, most  recently as  Head of the department of
Preclinical  Development. She has been a member  of the R&D management for three
years, and the recent year also in the senior management team at Active Biotech.

The  appointment will strengthen Active Biotech's R&D capabilities going forward
after  the recent positive results obtained  in the laquinimod and TASQ clinical

Lund, March 15, 2011
Active Biotech AB (publ)

For further information, please contact:
Tomas Leanderson
Tel: +46 (0)46 19 20 95
E-mail: tomas.leanderson@activebiotech.com

About Active Biotech
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases  and cancer. Projects  in or entering
pivotal  phase are laquinimod, an orally administered small molecule with unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally  administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.com  for more information.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active  Biotech  is  required  under  the  Securities  Markets  Act  to make the
information  in this  press release  public. The  information was  submitted for
publication at 3:00 pm CET on March 15, 2011.

Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE